Corbus Pharma (CRBP): Price-to-Revenue Ratio

Brandmark of Corbus Pharmaceuticals, Inc. (CRBP)

Strict supply regulations and the maintenance of strategic material reserves minimize risks for Corbus Pharmaceuticals (CRBP). The P/S time series visualizes the market valuation of this stability, where 69.50 reflects the metric's baseline. The business's resilience to crises is driven by the specific nature of clinical trials, while future capital is based on the commercialization of targeted antibody-drug conjugates for tumor treatment.

CRBP Corbus Pharmaceuticals P/S Multiple (07/04/2022 - 11/13/2022)

Corbus Pharmaceuticals (CRBP) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price Corbus Pharmaceuticals Holdings, Inc.|CRBP - Price Target Chart
- stock exchange capitalization data:
Market Value Corbus Pharmaceuticals|CRBP - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Corbus Pharmaceuticals|CRBP - Book Capitalization|Market Value to Equity Ratio corbuspharma.com|CRBP - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Corbus Pharmaceuticals|CRBP - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Corbus Pharmaceuticals Holdings|CRBP - Company Total Debt|Debt to Book Capital Corbus Pharmaceuticals, Inc.|CRBP - Company Long-Term Debts|Company Short-Term Loans and Borrowings Corbus Pharmaceuticals|Immediate Liquidity corbuspharma.com
- earnings and multiples data:
CRBP - Company Net Income|Expected Net Income Corbus Pharmaceuticals|CRBP - P/E Multiple|Forward P/E Multiple Corbus Pharmaceuticals, Inc.|CRBP - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Corbus Pharmaceuticals Holdings|CRBP - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRBP - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months corbuspharma.com|CRBP - Earnings per share growth in current year|Expected net earnings per share growth next year Corbus Pharmaceuticals
- issuer revenue and sales details:
CRBP - Company Revenue|Company Future Revenue Corbus Pharmaceuticals Holdings|CRBP - P/S Multiple|Price-to-Projected Revenue Ratio Corbus Pharmaceuticals Holdings|CRBP - Revenue Growth YoY (Last 12 Months)
Summary company analytics:Corbus Pharmaceuticals Holdings
Mass-produced product of Corbus Pharmaceuticals, Inc.

For the high-volatility clinical trial environment of the biotech sector, the estimated price-to-sales ratio for Corbus Pharmaceuticals (CRBP) serves as an overvaluation filter, benchmarking market capitalization against actual sales volume. Given investor skepticism stemming from past failures, this chart allows for the determination of the mathematical risk of purchasing an overheated asset and an assessment of the capital safety margin prior to the commercialization of new drugs.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio hutch-med.com HCM|Nuvation Corp - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Therapeutics|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics, Inc. HRTX|Market Cap to Revenue NVCT (Nuvectis Pharma, Inc.)|CHRS (Coherus BioSciences) - Market Capitalization-to-Revenue Ratio|Cardiff Oncology - Market Cap to Revenue|Market Cap to Sales Volume BYSI (BeyondSpring)|BioAtla - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings)|CTXR: P/S Multiple|Price to Sales cellectar.com (CLRB)|Price-to-Revenue Ratio BioLineRx|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple Kazia Therapeutics Ltd (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics Corp. SLXN|NCNA (nucana.com) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales Cyclacel|GTHX: P/S Multiple|Kronos Bio Corporation (KRON) - P/S Multiple|KTRA (kintara.com) - P/S Multiple|Market Cap to Revenue Ratio ONCT (Oncternal Therapeutics)|Price-to-Revenue Ratio Portage Biotech (PRTG)